Transgene Biotek Ltd to Approve Q4 Results for 2025 in Board Meeting on 13th February

Transgene Biotek Ltd has informed the BSE about a scheduled Board of Directors meeting on 13th February 2026. The meeting will consider and approve the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 31st December 2025, along with the Limited Review Report (Standalone & Consolidated) for the same quarter. The meeting will also transact other necessary business. The trading window for dealing in the securities of the company was closed from 1st January 2026 till 48 hours after the financial results become generally available information, in accordance with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018.